CN103271023B - Cell preservation solution with liquefying function for cervical exfoliated cell sample - Google Patents
Cell preservation solution with liquefying function for cervical exfoliated cell sample Download PDFInfo
- Publication number
- CN103271023B CN103271023B CN201310173184.7A CN201310173184A CN103271023B CN 103271023 B CN103271023 B CN 103271023B CN 201310173184 A CN201310173184 A CN 201310173184A CN 103271023 B CN103271023 B CN 103271023B
- Authority
- CN
- China
- Prior art keywords
- cell
- solution
- sample
- preservation solution
- cell preservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003761 preservation solution Substances 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 17
- 210000003679 cervix uteri Anatomy 0.000 claims abstract description 11
- 239000007853 buffer solution Substances 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 230000003204 osmotic effect Effects 0.000 claims abstract description 4
- 239000007864 aqueous solution Substances 0.000 claims abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- QEDXSHCYPROEOK-UHFFFAOYSA-N 3-phosphanylpropanoic acid Chemical class OC(=O)CCP QEDXSHCYPROEOK-UHFFFAOYSA-N 0.000 claims description 11
- 239000007983 Tris buffer Substances 0.000 claims description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 2
- 230000003139 buffering effect Effects 0.000 claims description 2
- 239000006174 pH buffer Substances 0.000 claims description 2
- 239000012488 sample solution Substances 0.000 claims 2
- 229960002668 sodium chloride Drugs 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000028327 secretion Effects 0.000 abstract description 10
- 239000003638 chemical reducing agent Substances 0.000 abstract description 9
- 238000001514 detection method Methods 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 102000053602 DNA Human genes 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 2
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 238000005336 cracking Methods 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 17
- 238000004321 preservation Methods 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 14
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000003097 mucus Anatomy 0.000 description 4
- 235000014666 liquid concentrate Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- YTBSYETUWUMLBZ-QWWZWVQMSA-N D-threose Chemical compound OC[C@@H](O)[C@H](O)C=O YTBSYETUWUMLBZ-QWWZWVQMSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a cervix cell preservation solution which comprises tris(2-carboxyethyl)phosphine hydrochloride, an osmotic pressure maintaining agent and an aqueous solution of pH (Potential Of Hydrogen) buffer solution components. The invention describes a novel cervix cell preservation solution which is characterized by comprising a stable reductant at a concentration of 0.1 to 1% and a formula used for the cervix cell preservation solution; and the cervix cell preservation solution under the coordination of the DNA (Deoxyribose Nucleic Acid) direct cracking method can be used for well solving the problems of more secretion and high viscidity of a ervical exfoliated cell sample and improving the sensitivity in detection of the cervical exfoliated cell.
Description
Technical field
The cell-preservation liquid of the present invention's generality design containing a kind of reductant, can destroy viscous protein matter secondary structure, and make containing the more cervical exfoliated cell sample liquefaction of viscous secretion, the DNA contributing to sample extracts and detects.
Background technology
When the cervical exfoliated cell of conventional cervical smear sampling carries out DNA and RNA analysis, often have sample vaginal secretion secretion many, be difficult to obtain enough cervical exfoliated cells when carrying out foranalysis of nucleic acids, sample is first carried out liquefaction process by general needs.The viscosity of secretion is very large, and the viscous protein matter mainly containing secretion is many.In mucus, moisture accounts for 95%, and large molecule mucoprotein accounts for 2% ~ 3%, and protein accounts for 0.1% ~ 0.5%, and the chemical structural formula of mucus, is attached on sugary protein side chain by disulfide bond crosslinking for main chain with a kind of protein.Conventional liquefaction principle is that secretory protein material is carried out degenerative treatments, such as, add NaOH, DTT etc.NaOH is alkaline matter, can directly by protein denaturation, but pH of sample is about the DNA direct detecting method of about 7 when needing application of sample for those, to need in sample after denaturing samples and, pH value is made to be adjusted to neutrality, carry out PCR so that follow-up or other are analyzed, and alkaline denaturation can destroy cell, thus alkaline denaturation to direct-detection DNA, RNA and need to keep some detection methods of cellular morphology inapplicable.Dithiothreitol (DTT) (Dithiothreitol, referred to as DTT) is a kind of Small molecular organic reducing agent, and chemical formula is C
4h
10o
2s
2.Be linear molecule under its reducing state, after oxidized, become the six-membered cyclic structure comprising disulfide bond.The name of dithiothreitol (DTT) is derived from threose (a kind of four carbon monose).DTT is also usually used to the reduction of disulfide bond in protein, can be used for stoping in the protein molecule that formed between the cysteine in protein or intermolecular disulfide bond.But DTT often cannot reduce the disulfide bond being embedded in protein structure inside (solvent is unreachable).Because DTT can go back the disulfide bond of crude protein, make protein denaturation, be usually used in the liquefaction of secretion, the liquefaction etc. of such as phlegm.Due to easy oxidation by air, the therefore less stable of DTT; But freezen protective or in inert gas process can extend its service life.Because the nucleophilicity of protonated sulphur is lower, along with the reduction of pH value, effective reproducibility of DTT also decreases; DTT also has peculiar smell, harmful.Therefore be necessary the method using the reductant of colorless and odorless, stable in properties to liquefy for the cervical cell more containing secretion, improve the efficiency that DNA extracts.
Summary of the invention
The present invention describes a kind of new cervix cell preservation solution, it is characterized in that being the stable reductant of 0.1-1% containing a kind of concentration, for the formula of cervix cell preservation solution, coordinate the method for DNA By Direct Pyrolysis, the cervical exfoliated cell sample that the more viscosity of secretion is larger can be solved preferably, add the sensitivity that cervical exfoliated cell detects.The title that the present invention relates to a kind of reductant is three (2-carboxyethyl) phosphonium salt hydrochlorate, and English name is that Tris (2-carboxyethyl) phosphine(is abbreviated as: TCEPHCl, and molecular formula is C
9h
16o
6pCl), TCEPHCl molecular structure is as follows:
TCEPHCl is a kind of reductant of not sulfur-bearing, can reduce the disulfide bond of protein molecule, colorless and odorless, to air-stable, and the functional group reaction in discord protein, non-volatile, at room temperature can keep stable, easy to use.The present invention studies the working concentration of this reductant, use high concentration can to degrade faster mucus, but can the TAQ enzyme in PCR reactant liquor be impacted, the time that adding needs more to grow at least could degrade mucus, be 0.1-1% through repeatedly groping to obtain good working concentration with experimental verification, the sample more containing vaginal fluid that the viscosity that can liquefy in 5 minutes to 15 minutes is larger, makes DNA extract more effective.It is large and need the preservation of other cells and the liquifying method of liquefaction that the method is equally applicable to viscosity.
Simultaneously cell-preservation liquid feature includes pH buffer, and preferred buffering range is at pH6.8-pH7.4; PH buffer can be phosphate buffer (PBS), Tris/HCl or PIPES, and concentration range is at 2.5mM-10mM; Cell-preservation liquid contains osmotic pressure and maintains agent, and its component content is 0.6-9% sodium chloride.
Embodiment
Embodiment 1
The working concentration of the present embodiment research three (2-carboxyethyl) phosphine.Use formula 1(containing the formula 1 cell-preservation liquid concentrate of three (2-carboxyethyl) phosphine of 0.5%, 10mM Tris/HCl (pH7.0) solution of 0.9%NaCl.Use formula 2(containing the cell-preservation liquid of three (2-carboxyethyl) phosphine of 5%, the 10mM Tris/HCl solution of 0.9%NaCl), be mixed with formula 2 concentrating cells conserving liquid.All add concentrated cell-preservation liquid according to the ratio of 1 to 4 in use, namely get cell-preservation liquid concentrate described in 0.5ml, add the cervical cell sample that 2ml contains more secretion; Get 30 routine samples, with normal saline dilution to 6ml, sample mean is divided into 3 parts, every this 2ml of increment.Sample is divided into 3 groups, the 1st group of sample, according to the ratio of 1 to 4, namely each sample adds described formula 1 cell-preservation liquid concentrate 0.5ml respectively, is three (2-carboxyethyl) phosphine of 0.1% in sample containing final concentration; 2nd group of sample, according to the ratio of 1 to 4, each sample adds the concentrated also 0.5ml of cell-preservation liquid respectively, is three (2-carboxyethyl) phosphine of 1% in sample containing final concentration; 3rd group of sample is control group, and each sample adds respectively not containing the 10mM Tris/HCl solution 0.5ml of the 0.9%NaCl of reductant.Effect before and after inspection process.Before treatment, because viscosity is comparatively large, the amount being difficult to draw fixed volume extracts detection for follow-up DNA, and sample tube turned upside down, observing liquid in sample can not flow fast, has hysteresis phenomenon; After the concentrating cells conserving liquid adding described formula 1, process 10-15 minute and can well liquefy sample, after being disposed, sample tube is turned upside down, can free flow be observed, use pipettor to draw like a cork simultaneously; 2nd group of sample, after the ratio according to 1 to 4 adds formula 2 concentrating cells conserving liquid, eliminates the time shorten of secretion viscosity to 5-10 minute, uses pipettor to draw like a cork; The function that control group does not then liquefy, the viscosity of sample tube does not change over the course of 15 mins.
Because cell can adapt to certain osmolarity ranges, we test containing the 10 routine samples of final concentration containing three (2-carboxyethyl) phosphine of 0.6%, the cell-preservation liquid of 0.6%NaCl, 2.5mM Tris/HCl, through three (2-carboxyethyl) phosphine process 10-15 minute, the effect reducing sample viscosity can be reached equally, observe the form of cast-off cells under the microscope, can see and contain in the cell-preservation liquid of 0.9%NaCl with final concentration in the cell-preservation liquid containing 0.6%NaCl containing final concentration, cellular morphology in sample all keeps complete, and the two is significantly not different.
Embodiment 2
Get the cervical exfoliated cell swab sample (sample that cell more) of 22 examples through sequence verification, fully suspend in 2ml physiological saline, each sample is respectively got the even packing of 1ml and is put into 2 new centrifuge tubes, one group of cell sample according to 1 to 5 ratio, formula 2 cell-preservation liquid getting 0.25ml adds wherein, other one group of sample adds 0.25ml containing 0.9%NaCl, the buffer solution (pH7.0) of 10mM Tris as a control group, liquefaction process is after 10 minutes, two groups of samples are used Human infectious warts virus parting detecting reagent (gene chips) to extract DNA respectively and detect HPV result (this kit manufactures (model is HPG48) by Genetel Pharmaceuticals (Shenzhen) Co., Ltd.).Each sample duplicate detection 1 time, the judgement that target spot signal value (INS value) is greater than 11 is the HPV positive (table 1), use the cell-preservation liquid process of described formula 2, in 22 routine samples, Absorbable organic halogens detects 8 routine positive sample, and control group uses physiological saline process, stable detection can go out 4 routine positive sample, other 2 routine samples repeat experiment and only have 1 detection positive.Prove to use formula of the present invention, the detection sensitivity of HPV in the lower sample of concentration can be improved.
Table 1. contrasts described cell-preservation liquid and physiological saline process viscosity cast-off cells sample HPV testing result
Note: the numeral target spot signal value (INS value) in bracket, the judgement that INS is greater than 11 is that HPV is positive.
Above content is in conjunction with concrete preferred embodiment further description made for the present invention, can not assert that specific embodiment of the invention is confined to these explanations.For general technical staff of the technical field of the invention, without departing from the inventive concept of the premise, some simple deduction or replace can also be made, all should be considered as belonging to protection scope of the present invention.
Claims (2)
1. a cervix cell preservation solution, is characterized in that, comprises a kind of three (2-carboxyethyl) phosphonium salt hydrochlorate, also maintains the aqueous solution of agent, pH buffer components containing osmotic pressure; The concentration of three (2-carboxyethyl) phosphonium salt hydrochlorate is 0.1%-1%; It is 0.6-0.9% sodium-chloride water solution that described osmotic pressure maintains agent; Described pH buffer solution is Tris/HCl buffer soln, and described pH buffer solution buffering range is between pH 6.8-7.4, and the concentration range of buffer solution component is between 2.5 mM-10 mM.
2. use the method for the cervix cell preservation solution liquefaction cervical cell described in claim 1,
Comprise step:
A) the concentrated cervix cell preservation solution that three (2-carboxyethyl) phosphine content is 0.5% to 5% is prepared;
B) ratio being 1 to 4 according to concentrated cervix cell preservation solution and cervical cell sample solution is got concentrated cervix cell preservation solution and is added in cervical cell sample solution;
C) static process 5 minutes is to 15 clocks.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310173184.7A CN103271023B (en) | 2013-05-11 | 2013-05-11 | Cell preservation solution with liquefying function for cervical exfoliated cell sample |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310173184.7A CN103271023B (en) | 2013-05-11 | 2013-05-11 | Cell preservation solution with liquefying function for cervical exfoliated cell sample |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103271023A CN103271023A (en) | 2013-09-04 |
CN103271023B true CN103271023B (en) | 2015-03-18 |
Family
ID=49053270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310173184.7A Expired - Fee Related CN103271023B (en) | 2013-05-11 | 2013-05-11 | Cell preservation solution with liquefying function for cervical exfoliated cell sample |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103271023B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112640888B (en) * | 2020-12-30 | 2022-05-03 | 深路医学科技(武汉)有限公司 | Cell preservation solution, preparation method thereof and cell preservation method |
CN113907064A (en) * | 2021-10-08 | 2022-01-11 | 广州达安基因股份有限公司 | Liquid-based cell preservation solution and preparation method thereof |
CN114410739B (en) * | 2021-11-26 | 2024-10-01 | 湖南大地同年生物科技有限公司 | RNA protective agent and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1321200A (en) * | 1998-08-12 | 2001-11-07 | 格莱恩比奥-奥内有限公司 | Vessel for blood sampling |
CN101363011A (en) * | 2008-09-17 | 2009-02-11 | 上海艾迪康临床检验中心有限公司 | Cervical exfoliated cell preservative fluid |
CN102258003A (en) * | 2010-05-28 | 2011-11-30 | 孝感市中心医院 | Liquid based cell preserving fluid |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2115123A4 (en) * | 2007-01-16 | 2010-07-07 | Applied Biosystems Llc | Selective lysis of sperm cells |
-
2013
- 2013-05-11 CN CN201310173184.7A patent/CN103271023B/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1321200A (en) * | 1998-08-12 | 2001-11-07 | 格莱恩比奥-奥内有限公司 | Vessel for blood sampling |
CN101363011A (en) * | 2008-09-17 | 2009-02-11 | 上海艾迪康临床检验中心有限公司 | Cervical exfoliated cell preservative fluid |
CN102258003A (en) * | 2010-05-28 | 2011-11-30 | 孝感市中心医院 | Liquid based cell preserving fluid |
Also Published As
Publication number | Publication date |
---|---|
CN103271023A (en) | 2013-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103789202B (en) | Normal temperature preserves the collection container of nucleic acid | |
Van Gulik | Fast sampling for quantitative microbial metabolomics | |
CN103271023B (en) | Cell preservation solution with liquefying function for cervical exfoliated cell sample | |
CN104381245A (en) | Reagent for stabilization of blood sample cells | |
CN107509722A (en) | Sample preservation liquid | |
CN106483228B (en) | The method of sulfur-containing amino acid in quantitative detection sludge | |
Andrade et al. | Chlorella vulgaris phycoremediation at low Cu+ 2 contents: Proteomic profiling of microalgal metabolism related to fatty acids and CO2 fixation | |
CN103454233A (en) | Method for measuring sulfide in environment | |
CN103088133B (en) | Detection method for sulfate reducing bacteria | |
CN102827933B (en) | Kit for qualitative detection of pinewood nematode and detection method thereof | |
Deng et al. | N-Methylimidazolium modified magnetic particles-assisted highly sensitive Escherichia coli detection based on polymerase chain reaction and capillary electrophoresis | |
Gamble et al. | Seasonal variability of diazotroph assemblages associated with the rhizosphere of the salt marsh cordgrass, Spartina alterniflora | |
Li et al. | Solid-phase microextraction of volatile organic compounds in headspace of PM-induced MRC-5 cell lines | |
CN105039306A (en) | Saliva protection agent | |
CN103571939A (en) | Fluorescent quantitative polymerase chain reaction (PCR) method for detecting tubercle bacillus infection from clinical specimen | |
CN101671646B (en) | HIV-1 integrase expression bacterial strain and integrase inhibitor in-vitro screening model | |
CN104480037A (en) | Method for screening phthalate degradation functional floras based on Biolog technique | |
CN107238664A (en) | The method for quantitatively detecting sulfur-containing amino acid in sludge | |
CN101245367B (en) | Semi-nested PCR method for detecting toxoplasma gondii | |
CN105621630B (en) | A kind of decoloration 'beta '-mannase and application thereof | |
CN108728579A (en) | A method of using the direct RT-PCR detections various plants virus of plant micro-assembly robot | |
CN107988209A (en) | A kind of nucleic acid extraction kit and its application | |
Ma et al. | Determination of total glutathione in yeasts by high-performance liquid chromatography with dansylation | |
CN107267497A (en) | A kind of universal total RNA extraction reagent box and method | |
Roth | Microbial Community Dynamics Involved in Organic Carbon Degradation and Mercury Methylation in Subarctic Peatlands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150318 |